Tags

Type your tag names separated by a space and hit enter

Teriflunomide, a potential novel cause of chronic active colitis.
Histopathology. 2020 Apr 23 [Online ahead of print]H

Abstract

Teriflunomide is a novel pyrimidine synthesis inhibitor which limits immune response by selectively blocking dihydroorotate dehydrogenase, required by rapidly dividing B and T lymphocytes [1]. It is indicated as a first-line treatment for relapsing-remitting multiple sclerosis (RRMS). The most common adverse reactions reported in patients receiving either 7 or 14 mg daily include headache (18% and 16%), elevated alanine aminotransferase (13% and 15%), diarrhea (13% and 14%), alopecia (10% and 13%), and nausea (8% and 11%), respectively [2].

Authors+Show Affiliations

Department of Pathology, University of Szeged, Albert Szent-Györgyi Health Center, Szeged, Hungary. H. Lee Moffitt Cancer Center & Research Institute and Departments of Pathology & Cell Biology and Oncologic Sciences, University of South Florida, Tampa, FL, USA.SaraPath Diagnostics &, Sarasota Memorial Hospital, Department of Pathology, Sarasota, FL, USA.Florida Digestive Health Specialists &, Florida State University College of Medicine at Sarasota Memorial Hospital, Sarasota, FL, USA.H. Lee Moffitt Cancer Center & Research Institute and Departments of Pathology & Cell Biology and Oncologic Sciences, University of South Florida, Tampa, FL, USA.

Pub Type(s)

Letter

Language

eng

PubMed ID

32323888

Citation

Kővári, Bence, et al. "Teriflunomide, a Potential Novel Cause of Chronic Active Colitis." Histopathology, 2020.
Kővári B, Zachs J, Murchie B, et al. Teriflunomide, a potential novel cause of chronic active colitis. Histopathology. 2020.
Kővári, B., Zachs, J., Murchie, B., & Lauwers, G. Y. (2020). Teriflunomide, a potential novel cause of chronic active colitis. Histopathology. https://doi.org/10.1111/his.14122
Kővári B, et al. Teriflunomide, a Potential Novel Cause of Chronic Active Colitis. Histopathology. 2020 Apr 23; PubMed PMID: 32323888.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Teriflunomide, a potential novel cause of chronic active colitis. AU - Kővári,Bence, AU - Zachs,Jeffrey, AU - Murchie,Brent, AU - Lauwers,Gregory Y, Y1 - 2020/04/23/ PY - 2020/4/24/entrez JF - Histopathology JO - Histopathology N2 - Teriflunomide is a novel pyrimidine synthesis inhibitor which limits immune response by selectively blocking dihydroorotate dehydrogenase, required by rapidly dividing B and T lymphocytes [1]. It is indicated as a first-line treatment for relapsing-remitting multiple sclerosis (RRMS). The most common adverse reactions reported in patients receiving either 7 or 14 mg daily include headache (18% and 16%), elevated alanine aminotransferase (13% and 15%), diarrhea (13% and 14%), alopecia (10% and 13%), and nausea (8% and 11%), respectively [2]. SN - 1365-2559 UR - https://www.unboundmedicine.com/medline/citation/32323888/Teriflunomide,_a_potential_novel_cause_of_chronic_active_colitis L2 - https://doi.org/10.1111/his.14122 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.